• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Proto Labs Inc.

    5/2/25 4:03:47 PM ET
    $PRLB
    Metal Fabrications
    Industrials
    Get the next $PRLB alert in real time by email
    prlb-20250331
    000144366912-312025Q1falseP3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesiso4217:XUAiso4217:EURxbrli:pure00014436692025-01-012025-03-3100014436692025-04-2500014436692025-03-3100014436692024-12-3100014436692024-01-012024-03-310001443669us-gaap:CommonStockMember2024-12-310001443669us-gaap:AdditionalPaidInCapitalMember2024-12-310001443669us-gaap:RetainedEarningsMember2024-12-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001443669us-gaap:CommonStockMember2025-01-012025-03-310001443669us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001443669us-gaap:RetainedEarningsMember2025-01-012025-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001443669us-gaap:CommonStockMember2025-03-310001443669us-gaap:AdditionalPaidInCapitalMember2025-03-310001443669us-gaap:RetainedEarningsMember2025-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001443669us-gaap:CommonStockMember2023-12-310001443669us-gaap:AdditionalPaidInCapitalMember2023-12-310001443669us-gaap:RetainedEarningsMember2023-12-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100014436692023-12-310001443669us-gaap:CommonStockMember2024-01-012024-03-310001443669us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001443669us-gaap:RetainedEarningsMember2024-01-012024-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001443669us-gaap:CommonStockMember2024-03-310001443669us-gaap:AdditionalPaidInCapitalMember2024-03-310001443669us-gaap:RetainedEarningsMember2024-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100014436692024-03-310001443669us-gaap:NoncompeteAgreementsMember2025-03-310001443669us-gaap:NoncompeteAgreementsMember2024-12-310001443669us-gaap:NoncompeteAgreementsMembersrt:MinimumMember2025-03-310001443669us-gaap:NoncompeteAgreementsMembersrt:MaximumMember2025-03-310001443669us-gaap:ComputerSoftwareIntangibleAssetMember2025-03-310001443669us-gaap:ComputerSoftwareIntangibleAssetMember2024-12-310001443669prlb:SoftwarePlatformMember2025-03-310001443669prlb:SoftwarePlatformMember2024-12-310001443669srt:EuropeMemberprlb:A3DHubsInc.HubsMember2021-01-222021-01-220001443669country:USprlb:A3DHubsInc.HubsMember2021-01-222021-01-2200014436692024-01-012024-12-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2025-03-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2025-03-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2025-03-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-12-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-12-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-12-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001443669us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-310001443669us-gaap:CorporateDebtSecuritiesMember2025-03-310001443669us-gaap:USStatesAndPoliticalSubdivisionsMember2025-03-310001443669us-gaap:USTreasuryBondSecuritiesMember2025-03-310001443669us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310001443669us-gaap:CorporateDebtSecuritiesMember2024-12-310001443669us-gaap:USStatesAndPoliticalSubdivisionsMember2024-12-310001443669us-gaap:USTreasuryBondSecuritiesMember2024-12-310001443669prlb:LongTermIncentivePlan2022Member2024-05-232024-05-230001443669prlb:LongTermIncentivePlan2022Member2025-01-012025-03-310001443669prlb:ESPPMember2025-01-012025-03-310001443669us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001443669us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001443669us-gaap:EmployeeStockOptionMember2025-03-310001443669us-gaap:RestrictedStockMembersrt:MinimumMember2025-01-012025-03-310001443669us-gaap:RestrictedStockMembersrt:MaximumMember2025-01-012025-03-310001443669us-gaap:RestrictedStockMember2024-12-310001443669us-gaap:RestrictedStockMember2025-01-012025-03-310001443669us-gaap:RestrictedStockMember2025-03-310001443669us-gaap:PerformanceSharesMember2025-03-310001443669us-gaap:PerformanceSharesMember2025-01-012025-03-310001443669us-gaap:PerformanceSharesMember2024-12-310001443669us-gaap:PerformanceSharesMember2024-01-012024-03-310001443669prlb:EmployeeStockPurchasePlanMember2025-01-012025-03-310001443669prlb:EmployeeStockPurchasePlanMember2024-01-012024-03-310001443669us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001443669us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001443669us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-01-012025-03-310001443669us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310001443669prlb:UnitedStatesSegmentMember2025-01-012025-03-310001443669prlb:EuropeSegmentMember2025-01-012025-03-310001443669us-gaap:CorporateAndOtherMember2025-01-012025-03-310001443669prlb:UnitedStatesSegmentMember2024-01-012024-03-310001443669prlb:EuropeSegmentMember2024-01-012024-03-310001443669us-gaap:CorporateAndOtherMember2024-01-012024-03-310001443669prlb:UnitedStatesSegmentMember2025-03-310001443669prlb:UnitedStatesSegmentMember2024-12-310001443669prlb:EuropeSegmentMember2025-03-310001443669prlb:EuropeSegmentMember2024-12-310001443669country:US2025-01-012025-03-310001443669country:US2024-01-012024-03-310001443669srt:EuropeMember2025-01-012025-03-310001443669srt:EuropeMember2024-01-012024-03-310001443669prlb:InjectionMoldingProtomoldMember2025-01-012025-03-310001443669prlb:InjectionMoldingProtomoldMember2024-01-012024-03-310001443669prlb:CNCMachiningFirstcutMember2025-01-012025-03-310001443669prlb:CNCMachiningFirstcutMember2024-01-012024-03-310001443669prlb:ThreeDPrintingFinelineMember2025-01-012025-03-310001443669prlb:ThreeDPrintingFinelineMember2024-01-012024-03-310001443669prlb:SheetMetalMember2025-01-012025-03-310001443669prlb:SheetMetalMember2024-01-012024-03-310001443669prlb:OtherProductsMember2025-01-012025-03-310001443669prlb:OtherProductsMember2024-01-012024-03-31
    Table of Contents
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________
    FORM 10-Q
    (Mark One)
    þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended March 31, 2025
    or
    oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from ___________ to ___________
    Commission File Number: 001-35435
    Proto Labs, Inc.
    (Exact name of registrant as specified in its charter)
    Minnesota41-1939628
    (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    5540 Pioneer Creek Drive
    Maple Plain, Minnesota
    55359
    (Address of principal executive offices)(Zip Code)
    (763) 479-3680
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name, former address and former fiscal year, if changed since last report)
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, Par Value $0.001 Per SharePRLBNew York Stock Exchange
    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þYes oNo
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). þYes oNo
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
    Large accelerated filerþAccelerated filer o
    Non-accelerated filero
    Smaller reporting companyoEmerging growth companyo
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). oYes þNo
    Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 23,770,640 shares of Common Stock, par value $0.001 per share, were outstanding at April 25, 2025.


    Table of Contents
    Proto Labs, Inc.
    TABLE OF CONTENTS
    ItemDescriptionPage
    PART I
    1.
    Financial Statements
    2
    2.
    Management's Discussion and Analysis of Financial Condition and Results of Operations
    16
    3.
    Quantitative and Qualitative Disclosures about Market Risk
    24
    4.
    Controls and Procedures
    24
    PART II
    1.
    Legal Proceedings
    25
    1A.
    Risk Factors
    25
    2.
    Unregistered Sales of Equity Securities and Use of Proceeds
    25
    3.
    Defaults Upon Senior Securities
    25
    4.
    Mine Safety Disclosures
    25
    5.
    Other Information
    25
    6.
    Exhibits
    26
    1

    Table of Contents
    PART I. FINANCIAL INFORMATION
    Item 1. Financial Statements
    Proto Labs, Inc.
    Consolidated Balance Sheets
    (In thousands, except share and per share amounts)
    March 31,
    2025
    December 31,
    2024
    (Unaudited)
    Assets
    Current assets
    Cash and cash equivalents$82,692 $89,071 
    Short-term marketable securities14,154 14,019 
    Accounts receivable, net of allowance for doubtful accounts of $2,103 and $1,975 as of March 31, 2025, and December 31, 2024, respectively
    73,904 66,504 
    Inventory13,202 12,305 
    Income taxes receivable864 2,906 
    Prepaid expenses and other current assets9,594 10,049 
    Total current assets194,410 194,854 
    Property and equipment, net221,207 227,263 
    Goodwill273,991 273,991 
    Other intangible assets, net20,775 21,422 
    Long-term marketable securities19,425 17,773 
    Operating lease assets2,461 2,993 
    Finance lease assets625 692 
    Other long-term assets4,556 4,524 
    Total assets$737,450 $743,512 
    Liabilities and shareholders' equity
    Current liabilities  
    Accounts payable$16,288 $15,504 
    Accrued compensation18,554 16,550 
    Accrued liabilities and other24,172 19,621 
    Current operating lease liabilities1,132 1,287 
    Current finance lease liabilities312 309 
    Income taxes payable1,634 — 
    Total current liabilities62,092 53,271 
    Long-term operating lease liabilities1,491 1,633 
    Long-term finance lease liabilities207 287 
    Long-term deferred tax liabilities12,062 13,565 
    Other long-term liabilities4,797 4,605 
    Total liabilities80,649 73,361 
    Shareholders' equity  
    Preferred stock, $0.001 par value, authorized 10,000,000 shares; issued and outstanding 0 shares as of each of March 31, 2025, and December 31, 2024
    — — 
    Common stock, $0.001 par value, authorized 150,000,000 shares; issued and outstanding 23,770,640 and 24,226,088 shares as of March 31, 2025, and December 31, 2024, respectively
    23 24 
    Additional paid-in capital447,115 453,705 
    Retained earnings236,554 244,406 
    Accumulated other comprehensive loss(26,891)(27,984)
    Total shareholders' equity656,801 670,151 
    Total liabilities and shareholders' equity$737,450 $743,512 
    The accompanying notes are an integral part of these consolidated financial statements.
    2

    Table of Contents
    Proto Labs, Inc.
    Consolidated Statements of Comprehensive Income
    (In thousands, except share and per share amounts)
    (Unaudited)
    Three Months Ended
    March 31,
    20252024
    Statements of Operations:
    Revenue$126,205 $127,890 
    Cost of revenue70,507 70,423 
    Gross profit55,698 57,467 
    Operating expenses  
    Marketing and sales23,749 23,160 
    Research and development10,609 11,167 
    General and administrative16,848 16,313 
    Benefits related to exit and disposal activities(39)— 
    Total operating expenses51,167 50,640 
    Income from operations4,531 6,827 
    Other income, net1,454 899 
    Income before income taxes5,985 7,726 
    Provision for income taxes2,386 2,458 
    Net income$3,599 $5,268 
    Net income per share:
    Basic$0.15 $0.21 
    Diluted$0.15 $0.20 
    Shares used to compute net income per share:
    Basic24,135,32025,624,949
    Diluted24,435,84425,784,987
    Comprehensive Income (net of tax)
    Comprehensive income$4,692 $4,436 
    The accompanying notes are an integral part of these consolidated financial statements.
    3

    Table of Contents
    Proto Labs, Inc.
    Consolidated Statements of Shareholders' Equity
    (In thousands, except share amounts)
    Common StockAdditional
    Paid-In
    Capital
    Retained
    Earnings
    Accumulated Other
    Comprehensive
    Loss
    Total
    SharesAmount
    Balance at December 31, 202424,226,088$24 $453,705 $244,406 $(27,984)$670,151 
    Common shares issued on exercise of options and other, net of shares withheld for tax obligations58,291 — (961)— — (961)
    Stock-based compensation expense— — 3,992 — — 3,992 
    Repurchases of common stock and other(513,739)(1)(9,621)(11,451)— (21,073)
     Net income— — — 3,599 — 3,599 
    Other comprehensive income
    Foreign currency translation adjustment— — — — 1,003 1,003 
    Net unrealized gains on investments in securities— — — — 90 90 
     Comprehensive income    4,692 
    Balance at March 31, 202523,770,640$23 $447,115 $236,554 $(26,891)$656,801 
    Common StockAdditional
    Paid-In
    Capital
    Retained
    Earnings
    Accumulated Other
    Comprehensive
    Loss
    Total
    SharesAmount
    Balance at December 31, 202325,721,957$26 $466,884 $256,398 $(28,013)$695,295 
    Common shares issued on exercise of options and other, net of shares withheld for tax obligations29,974— (533)— — (533)
    Stock-based compensation expense— — 4,276 — — 4,276 
    Repurchases of common stock(435,861)— (7,912)(8,252)— (16,164)
     Net income— — — 5,268 — 5,268 
    Other comprehensive income
    Foreign currency translation adjustment— — — — (925)(925)
    Net unrealized gains on investments in securities— — — — 93 93 
     Comprehensive income4,436 
    Balance at March 31, 202425,316,070$26 $462,715 $253,414 $(28,845)$687,310 
    The accompanying notes are an integral part of these consolidated financial statements.
    4

    Table of Contents
    Proto Labs, Inc.
    Consolidated Statements of Cash Flows
    (In thousands)
    (Unaudited)
    Three Months Ended
    March 31,
    20252024
    Operating activities
    Net income$3,599 $5,268 
    Adjustments to reconcile net income to net cash provided by operating activities:  
    Depreciation and amortization8,694 9,103 
    Stock-based compensation expense3,992 4,276 
    Deferred taxes(1,552)(2,247)
    Interest on finance lease obligations6 10 
    Impairments related to exit and closure of facilities219 — 
    Gain on disposal of property and equipment— (22)
    Other43 63 
    Changes in operating assets and liabilities:  
    Accounts receivable(7,405)(5,654)
    Inventories(698)802 
    Prepaid expenses and other517 (359)
    Income taxes3,702 5,457 
    Accounts payable758 (138)
    Accrued liabilities and other6,504 4,779 
    Net cash provided by operating activities18,379 21,338 
    Investing activities
    Purchases of property, equipment and other capital assets(1,262)(2,587)
    Proceeds from sales of property, equipment and other capital assets— 22 
    Purchases of marketable securities(6,552)— 
    Proceeds from call redemptions and maturities of marketable securities4,905 6,984 
    Net cash (used in) provided by investing activities(2,909)4,419 
    Financing activities
    Proceeds from issuance of common stock from equity plans287 — 
    Purchases of shares withheld for tax obligations(1,248)(533)
    Repurchases of common stock(20,890)(16,013)
    Principal repayments of finance lease obligations(76)(73)
    Net cash used in financing activities(21,927)(16,619)
    Effect of exchange rate changes on cash and cash equivalents78 (124)
    Net (decrease) increase in cash and cash equivalents(6,379)9,014 
    Cash and cash equivalents, beginning of period89,071 83,790 
    Cash and cash equivalents, end of period$82,692 $92,804 
    The accompanying notes are an integral part of these consolidated financial statements.
    5

    Table of Contents
    Notes to Consolidated Financial Statements
    Note 1 – Basis of Presentation
    The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Protolabs, the Company, we, us or our) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying financial statements reflect all adjustments necessary for a fair presentation of the Company’s statements of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal, recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
    The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (SEC) on February 21, 2025.
    The accompanying Consolidated Balance Sheet as of December 31, 2024 was derived from the audited Consolidated Financial Statements but does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K filed on February 21, 2025 as referenced above.
    Note 2 – Recent Accounting Pronouncements
    The Company did not recently adopt any accounting pronouncements that had a material impact on the Company's Consolidated Financial Statements.
    In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, that enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The Company is required to adopt this guidance for its annual year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.
    In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to improve disclosures about a public business entity's expenses, primarily through additional disaggregation of income statement expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating ASU 2024-03 to determine the impact on the Company's disclosures.
    Note 3 – Net Income per Common Share
    Basic net income per share is computed based on the weighted-average number of common shares outstanding. Diluted net income per share is computed based on the weighted-average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. Performance stock units are excluded from the calculation of dilutive potential common shares until the performance conditions have been satisfied. Anti-dilutive options were excluded from the calculation of diluted weighted average shares outstanding and were 436,669 and 421,937 for the three months ended March 31, 2025 and 2024, respectively.
    6

    Table of Contents
    The table below sets forth the computation of basic and diluted net income per share:
    Three Months Ended
    March 31,
    (in thousands, except share and per share amounts)20252024
    Net income$3,599 $5,268 
    Basic - weighted-average shares outstanding:24,135,32025,624,949
    Effect of dilutive securities:
    Employee stock options and other300,524160,038
    Diluted - weighted-average shares outstanding:24,435,84425,784,987
    Net income per share:
    Basic$0.15 $0.21 
    Diluted$0.15 $0.20 
    Note 4 – Goodwill and Other Intangible Assets
    There were no changes in the carrying amount of goodwill during the three months ended March 31, 2025.
    Intangible assets other than goodwill at March 31, 2025 and December 31, 2024 were as follows:
    March 31, 2025December 31, 2024Useful
    Life (in years)
    Weighted Average
    Useful Life Remaining
    (in years)
    (in thousands)GrossAccumulated
    Amortization
    NetGrossAccumulated
    Amortization
    Net
    Intangible assets with finite lives:
    Non-compete agreement$829 $(739)$90 $819 $(703)$116 
    2.0 - 5.0
    0.6
    Software technology13,229 (9,465)3,764 13,229 (9,123)4,106 10.02.8
    Software platform26,119 (9,198)16,921 25,657 (8,457)17,200 12.07.8
    Total intangible assets$40,177 $(19,402)$20,775 $39,705 $(18,283)$21,422 
    Intangible assets allocated to the Protolabs Network entities consisted of intangible assets of €11.6 million in Europe and $16.6 million in the United States as of the date of the acquisition. The Euro denominated intangible assets are translated at the end of each period using the current exchange rates resulting in a foreign currency translation adjustment that is recorded as a component of Other Comprehensive Income. Foreign currency unrealized losses related to intangible assets were $1.6 million and $2.2 million as of March 31, 2025 and December 31, 2024, respectively. Amortization expense for intangible assets was $0.9 million and $1.0 million for each of the three months ended March 31, 2025 and 2024, respectively.
    7

    Table of Contents
    Estimated aggregated amortization expense based on the current carrying value of the amortizable intangible assets and current exchange rates is as follows:
    (in thousands)Estimated Amortization Expense
    Remaining 2025$2,728
    20263,537
    20273,528
    20282,161
    20292,161
    Thereafter6,660
    Total estimated amortization expense$20,775
    Note 5 – Fair Value Measurements
    Accounting Standards Codification, Fair Value Measurement (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:
    Level 1—Quoted prices in active markets for identical assets or liabilities.
    Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
    The Company's assets and liabilities that are required to be measured or disclosed at fair value on a recurring basis include cash and cash equivalents and marketable securities. The Company’s cash consists of bank deposits and cash equivalents consist primarily of money market mutual funds. The Company determines the fair value of these investments using Level 1 inputs. The Company's marketable securities consist of short-term and long-term agency, municipal, corporate and other debt securities. Fair value for the corporate debt securities is primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).
    The following table summarizes financial assets as of March 31, 2025 and December 31, 2024 measured at fair value on a recurring basis:
    March 31, 2025December 31, 2024
    (in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
    Financial Assets:
    Cash$81,162 $— $— $86,366 $— $— 
    Money market mutual fund1,530 $— — 2,705 — — 
    Marketable securities18,211 15,368 — 17,261 14,531 — 
    Total$100,903 $15,368 $— $106,332 $14,531 $— 
    8

    Table of Contents
    Note 6 – Marketable Securities
    The Company invests in short-term and long-term agency, municipal, corporate and other debt securities. The securities are categorized as available-for-sale and are recorded at fair value. The following table summarizes information regarding the Company’s short-term and long-term marketable securities as of March 31, 2025 and December 31, 2024:
    March 31, 2025
    (in thousands)CostUnrealized GainsUnrealized LossesFair Value
    U.S. government agency securities$5,325 $— $(4)$5,321 
    Corporate debt securities15,882 — (38)15,844 
    U.S. municipal securities11,425 13 (26)11,412 
    U.S. treasury bonds1,000 2 — 1,002 
    Total marketable securities$33,632 $15 $(68)$33,579 
    December 31, 2024
    (in thousands)CostUnrealized GainsUnrealized LossesFair Value
    U.S. government agency securities$8,323 $— $(22)$8,301 
    Corporate debt securities15,852 — (82)15,770 
    U.S. municipal securities6,762 — (38)6,724 
    U.S. treasury bonds1,000 — (3)997 
    Total marketable securities$31,937 $— $(145)$31,792 
    Fair values for the corporate debt securities are primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).
    Classification of marketable securities as current or non-current is based upon the security’s maturity date as of the date of these financial statements.
    The March 31, 2025 balance of available-for-sale debt securities by contractual maturity is shown in the following table at fair value. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
    (in thousands)March 31,
    2025
    Due in one year or less$14,154 
    Due after one year through five years19,425 
    Total marketable securities$33,579 
    Note 7 – Inventory
    Inventory consists primarily of raw materials, which are recorded at the lower of cost and net realizable value using the standard cost method, which approximates first-in, first-out (FIFO) cost. The Company periodically reviews its inventory for slow-moving, damaged and discontinued items and provides allowances to reduce such items identified to their recoverable amounts.
    9

    Table of Contents
    The Company’s inventory consisted of the following as of the dates indicated:
    (in thousands)March 31,
    2025
    December 31,
    2024
    Total inventory$13,889 $12,989 
    Allowance for obsolescence(687)(684)
    Inventory, net of allowance$13,202 $12,305 
    Note 8 – Stock-Based Compensation
    On July 8, 2022, the board of directors approved the Proto Labs, Inc. 2022 Long-Term Incentive Plan, which was approved by the Company's shareholders at a Special Meeting of Shareholders on August 29, 2022, and subsequently amended and restated by the Company's shareholders at the Annual Meeting of Shareholders on May 23, 2024 (as amended and restated, the 2022 Plan) to increase the number of shares available for issuance pursuant to awards under the 2022 Plan by an additional 430,000 shares, add a minimum vesting requirement, and extend the expiration date so that the term of the 2022 Plan runs for ten years from the date of the shareholder approval. Under the 2022 Plan, the Company has the ability to grant stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, other stock-based awards and cash incentive awards. Awards under the 2022 Plan have a maximum term of ten years from the date of grant. The compensation and talent committee may provide that the vesting or payment of any award will be subject to the attainment of specified performance measures in addition to the satisfaction of any continued service requirements and the compensation and talent committee will determine whether such measures have been achieved. The per-share exercise price of stock options and SARs granted under the 2022 Plan generally may not be less than the fair market value of a share of our common stock on the date of the grant.
    The Company also has outstanding awards under the 2012 Long-Term Incentive Plan, as amended (the 2012 Plan), although the plan expired in February 2022 and no additional awards have since been or will be made under the 2012 Plan. The 2012 Plan provided the Company the ability to grant stock options, SARs, restricted stock, restricted stock units, other stock-based awards and cash incentive awards. Awards under the 2012 Plan that subsequently expired, were forfeited or cancelled, or settled in cash after August 29, 2022 became available for awards under the 2022 Plan.
    Employee Stock Purchase Plan
    The Company’s 2012 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase a variable number of shares of the Company’s common stock each offering period at a discount through payroll deductions of up to 15 percent of their eligible compensation, subject to plan limitations. The ESPP provides for six-month offering periods with a single purchase period ending May 15 and November 15, respectively. At the end of each offering period, employees are able to purchase shares at 85 percent of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.
    Stock-Based Compensation Expense
    Stock-based compensation expense was $4.0 million and $4.3 million for the three months ended March 31, 2025 and 2024, respectively.
    10

    Table of Contents
    Stock Options
    The following table summarizes stock option activity during the three months ended March 31, 2025:
    Stock OptionsWeighted-
    Average
    Exercise Price
    Options outstanding at December 31, 2024445,136$51.34 
    Granted77,60639.61 
    Exercised(8,502)33.79 
    Forfeited(1,404)32.63 
    Expired(13,136)92.09 
    Options outstanding at March 31, 2025499,700$48.80 
    Exercisable at March 31, 2025220,489$63.63 
    The outstanding options generally have a term of ten years. For employees, options granted become exercisable ratably over the vesting period, which is generally a period of four years, beginning on the first anniversary of the grant date, subject to the employee’s continuing service to the Company.
    The weighted-average grant date fair value of options that were granted during the three months ended March 31, 2025 was $22.07.
    The following table provides the assumptions used in the Black-Scholes pricing model valuation of options during the three months ended March 31, 2025 and 2024:
    Three Months Ended
    March 31,
    20252024
    Risk-free interest rate4.13%4.28%
    Expected life (years)
    6.25
    6.25
    Expected volatility
    52.99%
    50.62%
    Expected dividend yield0%0%
    As of March 31, 2025, there was $4.8 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.9 years.
    Restricted Stock
    Restricted stock awards are share-settled awards and restrictions lapse ratably over the vesting period, which is generally a period from three to four years, beginning on the first anniversary of the grant date, subject to the employee's continuing service to the Company. For the board of directors, restrictions generally lapse in full on the first anniversary of the grant date.
    11

    Table of Contents
    The following table summarizes restricted stock activity during the three months ended March 31, 2025:
    Restricted
    Stock
    Weighted-
    Average
    Grant Date
    Fair Value
    Per Share
    Restricted stock at December 31, 2024763,261$38.25 
    Granted63,12039.61 
    Restrictions lapsed(44,523)44.82 
    Forfeited(11,502)35.31 
    Restricted stock at March 31, 2025770,356$38.02 
    As of March 31, 2025, there was $18.1 million of unrecognized compensation expense related to non-vested restricted stock, which is expected to be recognized over a weighted-average period of 2.7 years.
    Performance Stock
    Performance stock units (PSUs) are expressed in terms of a target number of PSUs, with anywhere between 0 percent and 200 percent of that target number capable of being earned and vesting at the end of a three-year performance period depending on the Company’s performance in the final year of the performance period and the award recipient’s continued employment. The Company’s PSUs are based on market conditions and the related compensation cost is based on the fair value at grant date calculated using a Monte Carlo pricing model.
    The following table summarizes performance stock activity during the three months ended March 31, 2025:
    Performance
    Stock
    Weighted-
    Average
    Grant Date
    Fair Value
    Per Share
    Performance stock at December 31, 2024180,173$60.75 
    Granted66,59262.36 
    Restrictions lapsed(32,977)96.41
    Performance change—— 
    Forfeited——
    Performance stock at March 31, 2025213,788$55.75 
    The following table provides the assumptions used in the Monte Carlo pricing model valuation of PSUs during the three months ended March 31, 2025 and 2024:
    Three Months Ended
    March 31,
    20252024
    Risk-free interest rate4.08%4.37%
    Expected life (years)2.852.88
    Expected volatility52.40%
    51.40%
    Expected dividend yield0%0%
    12

    Table of Contents
    As of March 31, 2025, there was $7.5 million of unrecognized compensation expense related to non-vested performance stock, which is expected to be recognized over a weighted-average period of 2.3 years.
    Employee Stock Purchase Plan
    The following table presents the assumptions used to estimate the fair value of the ESPP during the three months ended March 31, 2025 and 2024:
    Three Months Ended
    March 31,
    20252024
    Risk-free interest rate
    4.29%
    5.16%
    Expected life (months)6.006.00
    Expected volatility
    65.60%
    47.92%
    Expected dividend yield0%0%
    Note 9 – Accumulated Other Comprehensive Income (Loss)
    Other comprehensive income (loss) is comprised of foreign currency translation adjustments and net unrealized gains (losses) on investments in securities.
    The following table presents the changes in accumulated other comprehensive income (loss) balances during the three months ended March 31, 2025 and 2024:
    Three Months Ended
    March 31,
    (in thousands)20252024
    Balance at beginning of period$(27,984)$(28,013)
    Foreign currency translation adjustments
    Other comprehensive income (loss) before reclassifications1,003 (925)
    Amounts reclassified from accumulated other comprehensive loss— — 
    Net current-period other comprehensive income (loss)1,003 (925)
    Net unrealized gains on investments in securities
    Other comprehensive income before reclassifications90 93 
    Amounts reclassified from accumulated other comprehensive loss— — 
    Net current-period other comprehensive income90 93 
    Balance at end of period$(26,891)$(28,845)
    Note 10 – Income Taxes
    The Company is subject to income tax in multiple jurisdictions and the use of estimates is required to determine the provision for income taxes. For the three months ended March 31, 2025 and 2024, the Company recorded an income tax provision of $2.4 million and $2.5 million, respectively. The income tax provision is based on the estimated annual effective tax rate for the year applied to pre-tax income. The effective income tax rate for the three months ended March 31, 2025 was 39.9 percent compared to 31.8 percent in the same period of the prior year. The effective tax rate increased by 8.1 percent for the three months ended March 31, 2025 when compared to the same period in 2024, primarily due to a one-time release of tax reserves arising from a successful audit closure in 2024 that did not repeat in 2025.
    13

    Table of Contents
    The effective income tax rate for the three months ended March 31, 2025 differs from the U.S. federal statutory rate of 21.0 percent due to various factors, including operating in multiple state and foreign jurisdictions partially offset by tax credits for which the Company qualifies.
    The Company had unrecognized tax benefits totaling $3.5 million as of March 31, 2025 and $3.4 million as of December 31, 2024, respectively, that if recognized would result in a reduction of the Company’s effective tax rate. The liabilities are classified as other long-term liabilities in the accompanying consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters in income tax expense and reports the liability in current or long-term income taxes payable as appropriate.
    Note 11 – Segment Reporting
    The Company’s reportable segments are based on the internal reporting used by the Company’s Chief Executive Officer, who is the chief operating decision maker (CODM), to assess operating performance and make decisions about the allocation of resources. The Company’s reportable segments are based upon geographic region, consisting of the United States and Europe. The Corporate Unallocated category includes non-reportable segments, as well as research and development and general and administrative costs that the Company does not allocate directly to its operating segments.
    Intercompany transactions primarily relate to intercontinental activity and have been eliminated and are excluded from the reported amounts. The difference between income from operations and pre-tax income relates to foreign currency-related gains and losses and interest income on cash balances and investments, which are not allocated to business segments.
    The following table summarizes selected financial information by reportable segments:
    Quarter Ended March 31 2025,
    (in thousands)
    United StatesEuropeCorporate UnallocatedTotal
    Revenue$100,267 $25,938 $— $126,205 
    Segment expenses1
    74,770 29,800 17,143 121,713 
    Exit, Disposal and Goodwill impairment benefit— (39)— (39)
    Income (Loss) from Operations$25,497 $(3,823)$(17,143)$4,531 
    Quarter Ended March 31 2024,
    (in thousands)
    United StatesEuropeCorporate UnallocatedTotal
    Revenue$101,481 $26,409 $— $127,890 
    Segment expenses1
    75,149 28,853 17,061 121,063 
    Exit, Disposal and Goodwill impairment costs— — — — 
    Income (Loss) from Operations$26,332 $(2,444)$(17,061)$6,827 
    1 Segment expenses consist primarily of raw materials, equipment depreciation, employee compensation including benefits, commissions and stock-based compensation, facilities costs and overhead allocations associated with the manufacturing process for molds and custom parts, marketing programs such as electronic, print and pay-per-click advertising and trade shows and other related costs for our United States and Europe reportable segments. Segment expenses for our Corporate Unallocated reportable segment consist primarily of personnel and outside service costs related to the development of new processes and product lines, enhancements of existing product lines, software developed for internal use, maintenance of internally developed software, quality assurance and
    14

    Table of Contents
    testing and employee compensation including benefits, stock-based compensation, professional service fees related to accounting, tax and legal, and other related overhead costs.
    Total long-lived assets, expenditures for additions to long-lived assets, and depreciation and amortization expense were as follows:
    (in thousands)March 31,
    2025
    December 31,
    2024
    Total long-lived assets:
    United States$176,428 $181,291 
    Europe44,779 45,972 
    Total Long-lived Assets$221,207 $227,263 
    Three Months Ended
    March 31,
    (in thousands)20252024
    Expenditures for additions to long-lived assets:
    United States$1,168 $834 
    Europe94 1,753 
    Total expenditures for additions to long-lived assets$1,262 $2,587 
    Three Months Ended
    March 31,
    (in thousands)20252024
    Depreciation and Amortization:
    United States$7,009 $7,325 
    Europe1,606 1,744 
    Corporate Unallocated79 34 
    Total depreciation and amortization$8,694 $9,103 
    Revenue by product line the three months ended March 31, 2025 and 2024 were as follows:
    Three Months Ended
    March 31,
    (dollars in thousands)20252024
    Revenue:
    Injection Molding$48,723 $52,663 
    CNC Machining52,843 49,932 
    3D Printing20,194 21,582 
    Sheet Metal4,211 3,553 
    Other Revenue234 160 
    Total Revenue$126,205 $127,890 
    15

    Table of Contents
    Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
    The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2024.
    Forward-Looking Statements
    Statements contained in this report regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our results to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in Item 1A. “Risk Factors” of this Form 10-Q, as well as our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC). Other unknown or unpredictable factors also could have material adverse effects on our future results. We cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, we expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
    Overview
    We are one of the world’s largest, fastest and most comprehensive digital manufacturers of custom parts. Our vision is accelerating innovation by revolutionizing manufacturing. Our mission is to shape the future by bringing customer ideas to life across every stage of their product cycle. We accomplish this by offering a variety of manufacturing capabilities fulfilled through a combination of owned manufacturing factories and a worldwide network of premium manufacturing partners. Our automated quoting and manufacturing systems are highly integrated with our manufacturing and fulfillment systems, which allow us to offer a vast array of manufacturing technologies in a variety of materials across a continuum of lead times and prices. Our technology-enabled digital engineering and manufacturing applications enable us to produce commercial-grade plastic, metal, and liquid silicone rubber parts in as fast as one day.
    Our customers conduct the majority of their business with us via our Internet-based eCommerce platform. We target our products to the millions of product developers and engineers who use three-dimensional computer-aided design (3D CAD) software to design products across a diverse range of end-markets, to the procurement and supply chain professionals seeking to easily and efficiently source custom parts on-demand, and to a wide variety of customers seeking to purchase custom parts. We believe our use of advanced technologies enable us to offer significant advantages at competitive prices to many customers and is the primary reason we have become a leading supplier of custom parts.
    We have established our operations in the United States and Europe. On October 21, 2024, the Company's board of directors approved a plan related to the Company's manufacturing facilities in Germany. The plan includes the closure of the Company's prototype injection molding manufacturing facility in Eschenlohe, Germany, and the discontinuation of Direct Metal Laser Sintering 3D printing services through its 3D printing facility in Putzbrunn, Germany. The Company expects to substantially complete the plan during fiscal year 2025. The Company intends to continue offering all of its manufacturing services to customers across Europe, including injection molding and metal 3D printing. These services will be fulfilled through internal manufacturing facilities and a network of manufacturing partners.
    Our primary manufacturing product lines currently include Injection Molding, CNC Machining, 3D Printing and Sheet Metal. We continually seek to expand the range of sizes and geometric complexity of the parts we can make with these processes, to extend the variety of materials we are able to support, and to identify additional manufacturing processes to which we can apply our technology or incorporate into our manufacturing network in order to better serve the evolving preferences and needs of our customers. With the addition of the Protolabs Network in 2021, our global network of premium manufacturing partners significantly expands the breadth and depth of our manufacturing capabilities, enabling us to offer customers a wider variety of lead times and pricing options, and an expanded envelope of parts (complexity, size, etc.).
    16

    Table of Contents
    Key Financial Measures and Trends
    Revenue
    Our operations are comprised of two geographic operating segments in the United States and Europe. On October 21, 2024, the Company's board of directors approved a plan related to the Company's manufacturing facilities in Germany. The plan includes the closure of the Company's prototype injection molding manufacturing facility in Eschenlohe, Germany, and the discontinuation of Direct Metal Laser Sintering 3D printing services through its 3D printing facility in Putzbrunn, Germany. The Company expects to substantially complete the plan during fiscal year 2025. The Company intends to continue offering all of its manufacturing services to customers across Europe, including injection molding and metal 3D printing. These services will be fulfilled through internal manufacturing facilities and a network of manufacturing partners.
    Revenue is derived from the sale or parts fulfilled through our owned manufacturing factories and worldwide network of premium manufacturing partners. Our product lines consist of Injection Molding, CNC Machining, 3D Printing and Sheet Metal. Injection Molding revenue consists of sales of custom injection molds and injection-molded parts. CNC Machining revenue consists of sales of CNC-machined custom parts. 3D Printing revenue consists of sales of 3D-printed parts. Sheet Metal revenue consists of sales of fabricated sheet metal custom parts. Our revenue is generated from a diverse customer base and our historical and current efforts to increase revenue have been directed at gaining new customers and selling to our existing customer base by increasing marketing and selling activities, including:
    •expanding the breadth and scope of our products by adding more sizes and materials to our offerings;
    •the introduction of our 3D Printing product line through our acquisition of FineLine in 2014;
    •expanding 3D Printing to Europe through our acquisition of Alphaform in 2015;
    •the introduction of our Sheet Metal product line through our acquisition of Rapid Manufacturing Group, LLC in 2017;
    •continuously improving the usability of our product lines such as our web-centric applications; and
    •providing customers with on-demand access to a global network of premium manufacturing partners through our acquisition of Hubs in 2021.
    The following table summarizes our unique customer contacts and revenue per customer contact:
    Three Months Ended March 31,
    20252024
    Revenue (in thousands)$126,205 $127,890 
    Customer contacts21,62722,466
    Revenue per customer contact1
    $5,836$5,693
    1 Revenue per customer contact is calculated using the revenue recognized during the respective period divided by the actual number of customer contacts served during the same period. Customer contacts are product developers, engineers, procurement and supply chain professionals and other individuals who place an order, and that order is shipped and invoiced during the period. The Company believes revenue per customer contact is useful to investors in evaluating the underlying business trends and ongoing operating performance of the Company.
    Cost of Revenue, Gross Profit and Gross Margin
    Cost of revenue consists primarily of raw materials, equipment depreciation, employee compensation including benefits and stock-based compensation, facilities costs, overhead allocations associated with the manufacturing process for molds and custom parts, and costs to procure parts through our network of premium manufacturing partners. We expect our personnel-related costs to increase in order to retain and attract top talent and remain competitive in the market. Overall, we expect cost of revenue to increase in absolute dollars.
    17

    Table of Contents
    We define gross profit as our revenue less our cost of revenue, and we define gross margin as gross profit expressed as a percentage of revenue. Our gross profit and gross margin are affected by many factors, including our mix of revenue produced in our internal manufacturing operations and outsourced to our external manufacturing partners, pricing, sales volume, manufacturing costs, the costs associated with increasing production capacity, the mix between domestic and foreign revenue sources, the mix of revenue by product line, and foreign currency exchange rates.
    Operating Expenses
    Operating expenses consist of marketing and sales, research and development and general and administrative expenses. Personnel-related costs are the most significant component in each of these categories.
    Our business strategy is to continue to be a leading online and technology-enabled manufacturer of quick-turn, on-demand injection-molded, CNC-machined, 3D-printed and fabricated sheet metal custom parts for prototyping and low-volume production. In order to achieve our goals, we anticipate continued substantial investments in technology and personnel, resulting in increased operating expenses in the future.
    Marketing and sales. Marketing and sales expense consists primarily of employee compensation, benefits, commissions, stock-based compensation, marketing demand generation costs such as electronic, print and pay-per-click advertising, trade shows and other related overhead. We expect sales and marketing expense to increase in the future as we increase the number of marketing and sales professionals and marketing demand generation costs targeted to increase our customer base and grow revenue.
    Research and development. Research and development expense consists primarily of personnel and outside service costs related to the development of new processes and product lines, enhancement of existing product lines, development of software for internal use, maintenance of internally developed software, quality assurance and testing. Costs for internal use software are evaluated by project and capitalized where appropriate under ASC 350-40, Intangibles — Goodwill and Other, Internal-Use Software. We expect research and development expense to increase in the future as we seek to enhance our e-commerce interface technology, internal software and supporting business systems, and continue to expand our product lines.
    General and administrative. General and administrative expense consists primarily of employee compensation, benefits, stock-based compensation, professional service fees related to accounting, tax and legal, and other related overhead. We expect general and administrative expense to increase in the future as we continue to grow and expand as a global organization.
    Benefits or costs related to disposal and exit activities. Costs related to disposal and exit activities is driven by our decision to close certain manufacturing facilities in Germany. The expenses consist primarily of operating expenses, including employee severance, write-down of fixed assets and facility-related charges. Benefits may result from adjustments to initial estimates regarding the nature and timing of disposal and exit activities.
    Other Income, net
    Other income, net primarily consists of foreign currency-related gains and losses and interest income on cash balances and investments. Our foreign currency-related gains and losses will vary depending upon movements in underlying foreign currency exchange rates. Our interest income will vary each reporting period depending on our average cash balances during the period, composition of our marketable security portfolio and the current level of interest rates.
    Provision for Income Taxes
    Provision for income taxes is comprised of federal, state, local and foreign taxes based on pre-tax income. Overall, our effective tax rate for 2025 and beyond may differ from historical effective tax rates due to increases in losses in foreign operations that are not eligible for tax benefits on account of valuation allowances, as well as any future tax law changes that may impact our effective tax rate.
    18

    Table of Contents
    Results of Operations
    The following table summarizes our results of operations and the related changes for the periods indicated. The results below are not necessarily indicative of the results for future periods.
    Three Months Ended March 31,Change
    (dollars in thousands)20252024$%
    Revenue$126,205 100.0 $127,890 100.0 $(1,685)(1.3)
    Cost of revenue70,507 55.9 70,423 55.1 84 0.1 
    Gross profit55,698 44.1 57,467 44.9 (1,769)(3.1)
    Operating expenses
    Marketing and sales23,749 18.8 23,160 18.1 589 2.5 
    Research and development10,609 8.4 11,167 8.7 (558)(5.0)
    General and administrative16,848 13.4 16,313 12.8 535 3.3 
    Benefits related to exit and disposal activities(39)— — — (39)(100.0)
    Total operating expenses51,167 40.5 50,640 39.6 527 1.0 
    Income from operations4,531 3.6 6,827 5.3 (2,296)(33.6)
    Other income, net1,454 1.2 899 0.7 555 61.7 
    Income before income taxes5,985 4.7 7,726 6.0 (1,741)(22.5)
    Provision for income taxes2,386 1.9 2,458 1.9 (72)(2.9)
    Net income$3,599 2.9 %$5,268 4.1 %$(1,669)(31.7)%
    Stock-based compensation expense included in the statements of operations data above for the three months ended March 31, 2025 and 2024 were as follows:
    Three Months Ended March 31,
    (dollars in thousands)20252024
    Stock options, restricted stock and performance stock$3,661 $3,955 
    Employee stock purchase plan331 321 
    Total stock-based compensation expense$3,992 $4,276 
    Cost of revenue$460 $459 
    Operating expenses:
      Marketing and sales778 832 
      Research and development625 693 
      General and administrative2,129 2,292 
    Total stock-based compensation expense$3,992 $4,276 
    19

    Table of Contents
    Comparison of Three Months Ended March 31, 2025 and 2024
    Revenue
    Revenue by reportable segment and the related changes for the three months ended March 31, 2025 and 2024 were as follows:
    Three Months Ended March 31,
    20252024Change
    (dollars in thousands)$% of Total Revenue$% of Total Revenue$%
    Revenue:
    United States$100,267 79.4 %$101,481 79.4 %$(1,214)(1.2)%
    Europe25,938 20.6 %26,409 20.6 %(471)(1.8)
    Total revenue$126,205 100.0 %$127,890 100.0 %$(1,685)(1.3 %)
    Our revenue decreased $1.7 million, or 1.3%, for the three months ended March 31, 2025 compared to the same period in 2024. The decline in revenue was primarily driven by the leap year in 2024, resulting in a decrease in the number of operating days in the three months ended March 31, 2025 compared to the same period in 2024. By reportable segment, revenue in the United States decreased $1.2 million, or 1.2%, for the three months ended March 31, 2025 compared to the same period in 2024. Revenue in Europe decreased $0.5 million, or 1.8%, for the three months ended March 31, 2025 compared to the same period in 2024. International revenue was negatively impacted by $0.5 million during the three months ended March 31, 2025 compared to the same period in 2024 as a result of foreign currency movements, primarily due to the weakening of the British Pound and Euro relative to the United States Dollar.
    During the three months ended March 31, 2025, we served 21,627 unique customer contacts, which is a decrease of 3.7% from the same period in 2024. Our customer contacts served decreased at a rate higher than our decrease in revenue. This was primarily due to our mix of customers served in the quarter as compared to the same period in 2024 and our strategic focus to earn larger orders from our customers as we strive to be their supplier of choice by serving their custom parts needs through the comprehensive offer of our factory and the Protolabs Network. Our revenue per customer contact grew 2.5% for the three months ended March 31, 2025 compared to the same period in 2024.
    Revenue by product line and the related changes for the three months ended March 31, 2025 and 2024 were as follows:
    Three Months Ended March 31,
    20252024Change
    (dollars in thousands)$% of Total Revenue$% of Total Revenue$%
    Revenue:
    Injection Molding$48,723 38.6 %$52,663 41.2 %$(3,940)(7.5)%
    CNC Machining52,843 41.9 %49,932 39.0 %2,911 5.8 
    3D Printing20,194 16.0 %21,582 16.9 %(1,388)(6.4)
    Sheet Metal4,211 3.3 %3,553 2.8 %658 18.5 
    Other Revenue234 0.2 %160 0.1 %74 46.3 
    Total Revenue$126,205 100.0 %$127,890 100.0 %$(1,685)(1.3)%
    By product line, our revenue decrease was driven by a 7.5% decrease in Injection Molding revenue and a 6.4% decrease in 3D Printing revenue, partially offset by a 5.8% increase in CNC Machining revenue, an 18.5% increase in Sheet Metal
    20

    Table of Contents
    revenue and a 46.3% increase in Other Revenue, in each case for the three months ended March 31, 2025 compared to the same period in 2024.
    Cost of Revenue, Gross Profit and Gross Margin
    Cost of Revenue. Cost of revenue increased $0.1 million, or 0.1%, for the three months ended March 31, 2025 compared to the same period in 2024, while revenue decreased 1.3% for the three months ended March 31, 2025 compared to the same period in 2024. The increase in the cost of revenue of $0.1 million was primarily driven by increases of $0.4 million in personnel and related costs during the three months ended March 31, 2025 compared to the same period in 2024, partially offset by decreases in equipment and facility-related costs of $0.3 million.
    Gross Profit and Gross Margin. Gross profit decreased $1.8 million, or 3.1% for the three months ended March 31, 2025 compared to the same period in 2024. Gross margin decreased from 44.9% in the three months ended March 31, 2024 to 44.1% in the three months ended March 31, 2025.
    Operating Expenses, Other Income, net and Provision for Income Taxes
    Marketing and Sales. Our marketing and sales expenses increased $0.6 million during the three months ended March 31, 2025 compared to the same period in 2024 primarily due to increases in personnel and related costs of $0.4 million primarily due to merit increases and incentive compensation related to commissions and $0.2 million in marketing program costs.
    Research and Development. Our research and development expenses decreased $0.6 million, or 5.0%, during the three months ended March 31, 2025 compared to the same period in 2024 primarily due to decreases in personnel and related costs of $0.4 million primarily due largely to lower contract labor spend and $0.4 million in professional services, partially offset by increases of $0.2 million in operating costs.
    General and Administrative. Our general and administrative expenses increased $0.5 million, or 3.3%, during the three months ended March 31, 2025 compared to the same period in 2024 primarily due to by increases of $1.0 million in administrative costs, partially offset by decreases in personnel and related costs of $0.2 million primarily due to lower headcount and $0.3 million in stock based compensation.
    Benefits related to exit and disposal. Our decision to exit and close certain operations in Germany resulted in less than $0.1 million in personnel and related cost benefits during the three months ended March 31, 2025. The benefit is the result of timing of employee separation payments and changes from estimated amounts accrued in 2024. We had no costs related to exit and disposal activities during the three months ended March 31, 2024.
    Other income, net. We recognized other income, net of $1.5 million for the three months ended March 31, 2025, an increase of $0.6 million compared to other income, net of $0.9 million for the three months ended March 31, 2024. Other income, net for the three months ended March 31, 2025 primarily consisted of $1.4 million in interest income on investments and other income. Other income, net for the three months ended March 31, 2024 primarily consisted of $1.1 million in interest income on investments and other income, partially offset by $0.2 million of foreign currency losses.
    Provision for Income Taxes. Our effective tax rate of 39.9% for the three months ended March 31, 2025 increased 8.1% compared to 31.8% for the same period in 2024. The increase in the effective tax rate was primarily due to a one-time release of tax reserves arising from a successful audit closure in 2024, that did not repeat in 2025. Our income tax provision of $2.4 million for the three months ended March 31, 2025 decreased $0.1 million as compared to our income tax provision of $2.5 million for the same period in 2024.
    21

    Table of Contents
    Liquidity and Capital Resources
    Cash Flows
    The following table summarizes our cash flows during the three months ended March 31, 2025 and 2024:
    Three Months Ended
    March 31,
    (dollars in thousands)20252024
    Net cash provided by operating activities$18,379 $21,338 
    Net cash (used in) provided by investing activities(2,909)4,419 
    Net cash used in financing activities(21,927)(16,619)
    Effect of exchange rate changes on cash and cash equivalents78 (124)
    Net (decrease) increase in cash and cash equivalents$(6,379)$9,014 
    Sources of Liquidity
    Historically, we have primarily financed our operations and capital expenditures through cash flow from operations. We had cash and cash equivalents of $82.7 million as of March 31, 2025, a decrease of $6.4 million from December 31, 2024. The decrease in our cash was primarily due to $1.3 million for purchases of property, equipment and other capital assets, $6.6 million for purchases of marketable securities and $20.9 million in repurchases of common stock, which were partially offset by cash provided by operating activities of $18.4 million and proceeds from call redemptions and maturities of marketable securities of $4.9 million.
    We believe that our existing cash and cash equivalents together with cash generated from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months.
    Cash Flows from Operating Activities
    Cash flows from operating activities were $18.4 million during the three months ended March 31, 2025 and primarily consisted of net income of $3.6 million, adjusted for certain non-cash items, including depreciation and amortization of $8.7 million, stock-based compensation expense of $4.0 million, changes in operating assets and liabilities and other items totaling $3.4 million and an impairment of a leased facility of $0.2 million, which were partially offset by deferred taxes of $1.6 million. Cash flows from operating activities were $21.3 million during the three months ended March 31, 2024 and primarily consisted of net income of $5.3 million, adjusted for certain non-cash items, including depreciation and amortization of $9.1 million, stock-based compensation expense of $4.3 million and changes in operating assets and liabilities and other items totaling $4.9 million, which were partially offset by deferred taxes of $2.2 million.
    Cash flows from operating activities decreased $3.0 million during the three months ended March 31, 2025 compared to the same period in 2024, primarily due to decreases in depreciation and amortization of $0.4 million, decreases in stock-based compensation of $0.3 million, decreases in net income of $1.7 million and changes in operating assets and liabilities totaling $1.5 million, which were partially offset by increases in deferred taxes of $0.7 million, and other property and equipment adjustments of $0.2 million.
    Cash Flows from Investing Activities
    Cash used in investing activities was $2.9 million during the three months ended March 31, 2025, consisting of $1.3 million for net purchases of property, equipment and other capital assets and $1.6 million of purchases of marketable securities, net of proceeds from call redemptions and maturities.
    Cash provided by investing activities was $4.4 million during the three months ended March 31, 2024, consisting of $7.0 million in proceeds from call redemptions and maturities of marketable securities, which were partially offset by $2.6 million for net purchases of property, equipment and other capital assets.
    22

    Table of Contents
    Cash Flows from Financing Activities
    Cash used in financing activities was $21.9 million during the three months ended March 31, 2025, consisting of $20.9 million in repurchases of common stock, $1.2 million in purchases of shares withheld for tax obligations associated with equity transactions and $0.1 million for repayments of finance lease obligations, which were partially offset by $0.3 million in proceeds related the exercise of non-qualified stock options.
    Cash used in financing activities was $16.6 million during the three months ended March 31, 2024, consisting of $16.0 million in repurchases of common stock, $0.5 million in purchases of shares withheld for tax obligations associated with equity transactions and $0.1 million for repayments of finance lease obligations.
    Critical Accounting Estimates
    We have adopted various accounting policies to prepare the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires us to make estimates, judgements and assumptions. Our significant accounting policies and estimates are disclosed in Note 2 to the Consolidated Financial Statements included Part II, Item 8 in our Annual Report on Form 10-K for the year ended December 31, 2024. There were no material changes to our critical accounting policies and estimates during the three months ended March 31, 2025.
    Recent Accounting Pronouncements
    For information on recent accounting pronouncements, see Note 2 to the Consolidated Financial Statements appearing in Part I, Item 1 in this Quarterly Report on Form 10-Q.
    23

    Table of Contents
    Item 3. Quantitative and Qualitative Disclosures about Market Risk
    Foreign Currency Risk
    As a result of our foreign operations, we have revenue, expenses, assets and liabilities that are denominated in foreign currencies. We generate revenue and incur production and sourcing costs and operating expenses in British Pounds and Euros.
    Our operating results and cash flows are adversely impacted when the United States Dollar appreciates relative to foreign currencies. Additionally, our operating results and cash flows are adversely impacted when the British Pound appreciates relative to the Euro. As we expand internationally, our results of operations and cash flows will become increasingly subject to changes in foreign currency exchange rates.
    We have not used forward contracts or currency borrowings to hedge our exposure to foreign currency risk. Foreign currency risk can be assessed by estimating the change in results of operations or financial position resulting from a hypothetical 10% adverse change in foreign exchange rates. We believe such a change would generally not have a material impact on our financial position, but could have a material impact on our results of operations. We recognized foreign currency gains of $0.1 million and foreign currency losses of $0.2 million for the three months ended March 31, 2025 and 2024, respectively. The changes in foreign exchange rates had an adverse impact on consolidated revenue of $0.5 million for the three months ended March 31, 2025 compared to the same period in 2024.
    Item 4. Controls and Procedures
    Evaluation of Disclosure Controls and Procedures
    Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures are effective and provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and within the time frames specified in the SEC’s rules and forms and accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
    Changes in Internal Control over Financial Reporting
    There have been no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
    24

    Table of Contents
    PART II. OTHER INFORMATION
    Item 1. Legal Proceedings
    From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of these financial statements, we do not believe we are party to any litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business.
    Item 1A. Risk Factors
    Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 includes a discussion of our risk factors. There have been no material changes from the risk factors described in our Form 10-K.
    Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    On February 4, 2025, our board of directors authorized a share repurchase program (the February 2025 Program). The February 2025 Program is open-ended and authorizes repurchases of shares of our common stock from time to time on the open market or in privately negotiated purchases, with a total stock repurchase authorized of up to $100 million. We have $79.1 million remaining under this authorization. The February 2025 Program does not obligate us to acquire any particular amount of shares of our common stock and remains in effect until the total authorized amount is expended or until further action by our board of directors. The actual timing, manner, number and value of shares repurchased under the February 2025 Program will be determined by our management in its discretion and will depend on several factors, including the market price of the Company's common stock, general market and economic conditions, applicable requirements, and other considerations.
    During the three months ended March 31, 2025, we repurchased 513,739 shares of our common stock at a total purchase price of $20.9 million under this program. Common stock repurchase activity through March 31, 2025 was as follows:
    PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as
    Part of Publicly Announced Plans or
    Programs
    Maximum Dollar Value of Shares that
    May Yet Be Purchased Under the Plans
    or Programs (in thousands) (1)
    January 1, 2025 through January 31, 2025—$— —$— 
    February 1, 2025 through February 28, 2025340,430$41.96 340,430$85,714 
    March 1, 2025 through March 31, 2025173,309$38.02 173,309$79,125 
    513,739$40.63 513,739$79,125 
    Item 3. Defaults Upon Senior Securities
    No matters to disclose.
    Item 4. Mine Safety Disclosures
    No matters to disclose.
    Item 5. Other Information
    During the three months ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
    25

    Table of Contents
    Item 6. Exhibits
    The following documents are filed as part of this report:
    Exhibit NumberDescription of Exhibit
    3.1
    Third Amended and Restated Articles of Incorporation of Proto Labs, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1/A, filed on February 13, 2012).
    3.2
    Articles of Amendment to Third Amended and Restated Articles of Incorporation of Proto Labs, Inc. dated May 20, 2015 (incorporated by reference to Exhibit 3.1 to the Company's Form 8-K, filed with the Commission on May 21, 2015).
    3.3
    Third Amended and Restated By-Laws of Proto Labs, Inc., as amended through November 15, 2022 (incorporated by reference to Exhibit 3.2 to the Company's Form 8-K, filed on November 15, 2022).
    31.1
    Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act*
    31.2
    Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act*
    32.1
    Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act**
    101.INSInline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)*
    101.SCHInline XBRL Taxonomy Extension Schema Document*
    101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
    101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
    101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
    101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
    104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

    *Filed herewith.
    **Furnished herewith.
    26

    Table of Contents
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    Proto Labs, Inc.
    Date: May 2, 2025
    /s/ Robert Bodor
    Robert Bodor
    President and Chief Executive Officer
    (Principal Executive Officer)
    Date: May 2, 2025
    /s/ Daniel Schumacher
    Daniel Schumacher
    Chief Financial Officer
    (Principal Financial Officer)
    27
    Get the next $PRLB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PRLB

    DatePrice TargetRatingAnalyst
    6/5/2024$44.00Overweight
    Cantor Fitzgerald
    8/4/2023Sell → Hold
    Craig Hallum
    2/13/2023Hold → Buy
    The Benchmark Company
    11/29/2022$29.00Buy
    Lake Street
    11/4/2022Hold → Sell
    Craig Hallum
    11/4/2022Buy → Hold
    Craig Hallum
    10/29/2021Buy → Hold
    Benchmark
    10/29/2021Buy → Hold
    The Benchmark Company
    More analyst ratings

    $PRLB
    SEC Filings

    See more
    • Proto Labs Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Proto Labs Inc (0001443669) (Filer)

      5/30/25 4:21:24 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • SEC Form SD filed by Proto Labs Inc.

      SD - Proto Labs Inc (0001443669) (Filer)

      5/29/25 3:03:03 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • SEC Form S-8 filed by Proto Labs Inc.

      S-8 - Proto Labs Inc (0001443669) (Filer)

      5/27/25 4:54:07 PM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Financials

    Live finance-specific insights

    See more
    • Protolabs Reports Financial Results for the First Quarter of 2025

      Total Revenue of $126.2 Million GAAP Earnings Per Share of $0.15, Non-GAAP Earnings Per Share of $0.33 Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue was $126.2 million, a 1.3% decrease compared to revenue of $127.9 million in the first quarter of 2024. Revenue fulfilled through the Protolabs Network was $26.3 million, a 10.0% increase compared to the first quarter of 2024. Net income was $3.6 million, or $0.15 per diluted share, compared to $5.3 million, or $0.20 per diluted shar

      5/2/25 6:00:00 AM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs Sets Conference Call to Discuss First Quarter 2025 Financial Results

      Protolabs (NYSE:PRLB) announced today that it will issue its financial results for the first quarter of 2025 before the opening of the market on Friday, May 2, 2025. Protolabs will host a conference call to discuss the results at 8:30 a.m. EDT on the same day. A simultaneous webcast of the call will be available via this link and at the investor relations section of the Protolabs website. To access the live call, please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least 5 minutes prior to the 8:30 a.m. EDT start time. An audio replay will be available at the investor relations section of the Protolabs website beginning approximately two hours following the end of the conferen

      4/11/25 9:00:00 AM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs Reports Financial Results for the Fourth Quarter and Full Year 2024

      2024 Revenue of $501 Million 2024 GAAP Earnings Per Share of $0.66, Non-GAAP Earnings Per Share of $1.63 Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue was $121.8 million, a 2.6% decrease compared to revenue of $125.0 million in the fourth quarter of 2023. Revenue fulfilled through the Protolabs Network was $26.5 million, a 17.9% increase compared to the fourth quarter of 2023. Net loss was $(0.4) million, or $(0.02) per diluted share, compared to $7.0 mil

      2/7/25 6:00:00 AM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Proto Labs Inc. (Amendment)

      SC 13G/A - Proto Labs Inc (0001443669) (Subject)

      2/14/24 12:19:19 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • SEC Form SC 13G/A filed by Proto Labs Inc. (Amendment)

      SC 13G/A - Proto Labs Inc (0001443669) (Subject)

      2/13/24 5:12:22 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • SEC Form SC 13G/A filed by Proto Labs Inc. (Amendment)

      SC 13G/A - Proto Labs Inc (0001443669) (Subject)

      1/22/24 2:03:09 PM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Black Archie C. was granted 3,939 shares, increasing direct ownership by 18% to 26,218 units (SEC Form 4)

      4 - Proto Labs Inc (0001443669) (Issuer)

      5/28/25 6:04:48 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Director Gawlick Rainer was granted 3,939 shares, increasing direct ownership by 10% to 42,168 units (SEC Form 4)

      4 - Proto Labs Inc (0001443669) (Issuer)

      5/28/25 5:54:32 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Director Chin Moonhie was granted 3,939 shares, increasing direct ownership by 24% to 20,096 units (SEC Form 4)

      4 - Proto Labs Inc (0001443669) (Issuer)

      5/28/25 5:54:04 PM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protolabs Announces Inducement Awards Under NYSE Rule 303A.08

      Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, announced that it granted certain equity awards on May 23, 2025, as a material inducement to Suresh Krishna, the Company's new President and Chief Executive Officer, entering employment with the Company. As previously disclosed, the Company and Krishna entered into an executive employment agreement in connection with Krishna's appointment as President and Chief Executive Officer. Pursuant to the executive employment agreement, the following inducement equity awards were granted to Krishna in accordance with New York Stock Exchange Listed Company Manual Rule 303A.08:

      5/23/25 5:31:00 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs Appoints Suresh Krishna as President and CEO

      Reaffirms Second Quarter 2025 Outlook Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced its Board of Directors has appointed Suresh Krishna as President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Krishna most recently served as President and Chief Executive Officer at Northern Tool + Equipment, a manufacturer and retailer of tools and commercial equipment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521200213/en/Suresh Krishna, President and CEO, Protolabs Krishna succeeds Rob Bodor, wh

      5/21/25 4:05:00 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs Reports Financial Results for the First Quarter of 2025

      Total Revenue of $126.2 Million GAAP Earnings Per Share of $0.15, Non-GAAP Earnings Per Share of $0.33 Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue was $126.2 million, a 1.3% decrease compared to revenue of $127.9 million in the first quarter of 2024. Revenue fulfilled through the Protolabs Network was $26.3 million, a 10.0% increase compared to the first quarter of 2024. Net income was $3.6 million, or $0.15 per diluted share, compared to $5.3 million, or $0.20 per diluted shar

      5/2/25 6:00:00 AM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Bodor Robert bought $99,800 worth of shares (3,480 units at $28.68), increasing direct ownership by 4% to 80,878 units (SEC Form 4)

      4 - Proto Labs Inc (0001443669) (Issuer)

      9/9/24 4:47:57 PM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Protolabs with a new price target

      Cantor Fitzgerald initiated coverage of Protolabs with a rating of Overweight and set a new price target of $44.00

      6/5/24 7:16:03 AM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs upgraded by Craig Hallum

      Craig Hallum upgraded Protolabs from Sell to Hold

      8/4/23 11:42:43 AM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs upgraded by The Benchmark Company

      The Benchmark Company upgraded Protolabs from Hold to Buy

      2/13/23 7:35:34 AM ET
      $PRLB
      Metal Fabrications
      Industrials

    $PRLB
    Leadership Updates

    Live Leadership Updates

    See more
    • Protolabs Appoints Suresh Krishna as President and CEO

      Reaffirms Second Quarter 2025 Outlook Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced its Board of Directors has appointed Suresh Krishna as President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Krishna most recently served as President and Chief Executive Officer at Northern Tool + Equipment, a manufacturer and retailer of tools and commercial equipment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521200213/en/Suresh Krishna, President and CEO, Protolabs Krishna succeeds Rob Bodor, wh

      5/21/25 4:05:00 PM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs Appoints Agnes Semington as Chief Human Resources Officer

      Semington will lead the digital manufacturer's global human resources organization Protolabs (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced Agnes Semington as its global Chief Human Resources Officer (CHRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231005723054/en/Protolabs' new Chief Human Resources Officer, Agnes Semington, will lead the digital manufacturer's global HR organization. (Photo: Business Wire) "We are very excited to welcome Agnes as the next leader of our human resources team at Protolabs," said Rob Bodor, President and CEO at Protolabs. "She has excelled at b

      10/5/23 10:00:00 AM ET
      $PRLB
      Metal Fabrications
      Industrials
    • Protolabs Appoints Oleg Ryaboy as New Chief Technology Officer

      Protolabs (NYSE:PRLB), a leading online and technology-enabled manufacturer, today announced Oleg Ryaboy as its new Global Chief Technology Officer effective September 9, 2022. "After an extensive search we're extremely excited to welcome Oleg to our leadership team," said Rob Bodor, CEO and President at Protolabs. "With an all-new e-commerce platform and the addition of a distributed network of suppliers, we're entering the next chapter of digital manufacturing. I'm confident Oleg's experience and expertise will help guide us into the future." Ryaboy joins the digital manufacturer after more than 12 years as a technology leader at Digital River, a global e-commerce platform and software-

      9/8/22 4:00:00 PM ET
      $PRLB
      Metal Fabrications
      Industrials